GLP-1 and constipation: A stepwise plan for managing constipation on Ozempic

Hunger-suppressing GLP-1 receptor agonists — including semaglutide (Ozempic) — can change gut motility and lead to a range of gastrointestinal effects. While nausea and diarrhea are common, many people also report constipation on Ozempic or other GLP-1 therapies. This article summarizes the evidence, gives a practical stepwise management plan, lists useful biomarkers to check, and highlights safety considerations and red flags.

How GLP‑1 medicines can affect bowel habits

GLP‑1 receptor agonists slow gastric emptying and alter intestinal transit in some people. The result can be:

• Less frequent bowel movements or harder stools for some users.

• Variable effects between individuals and between different GLP‑1 drugs/doses.

Clinical studies and post‑marketing reports document GI side effects across the class, and rates or severity may change with dose escalation. If constipation develops after starting or increasing a GLP‑1 dose, consider both symptomatic measures and a review of reversible causes.

Stepwise constipation plan (practical, conservative approach)

Start with the least invasive measures and escalate if needed. Discuss any medication changes with your clinician.

1) Check for reversible contributors and timing

• Review recent medication starts (including iron, opioids, anticholinergics) and supplements.

• Note onset relative to GLP‑1 initiation or dose increase.

• Consider adjusting meal timing (smaller, regular meals) and spacing of oral medications relative to injections per your clinician’s advice.

2) Hydration and activity

• Increase fluid intake if appropriate (aim for adequate daily fluids; individual needs vary).

• Regular physical activity and abdominal massage can improve transit for many people.

3) Dietary fiber — forms and how to use them

• Prefer soluble fiber (psyllium, methylcellulose) for forming softer bulky stools; start gradually to reduce bloating.

• Insoluble fiber (wheat bran) can help some people but may worsen symptoms in others.

• Increase fiber slowly over 1–2 weeks to allow adaptation and avoid excess gas.

4) Consider an osmotic laxative if fiber + fluids are insufficient

• Polyethylene glycol (PEG 3350) is widely used and effective for chronic constipation; typical OTC dosing is 17 g dissolved in water once daily, adjusted by symptom response under clinician guidance.

• Oral magnesium salts (magnesium citrate or magnesium oxide) can be effective but require attention to kidney function and concurrent medications — see biomarkers and safety below.

5) Stool softeners and stimulant laxatives

• Docusate sodium may be used as a stool softener when stools are hard.

• Short courses of stimulant laxatives (bisacodyl, senna) can help when transit is slow. Typical OTC dosing: bisacodyl 5–15 mg orally once daily or 10 mg rectal suppository as needed. Use stimulants sparingly and discuss longer-term plans with a clinician.

6) Rectal measures for immediate relief

• Glycerin suppositories or mineral oil may provide local relief for impacted stool.

• Enemas are an option when oral measures fail, but should be used under guidance if you suspect impaction.

7) Reassess medication strategy

• If constipation persists or is severe despite reasonable measures, review GLP‑1 dosing with your prescriber. Options include dose reduction, slower up‑titration, changing timing, or switching to a different GLP‑1 agent.

• Do not stop or alter prescribed medications without clinician approval.

Comparing common options (benefits and tradeoffs)

• Soluble fiber (psyllium): Generally safe; works over days; may cause gas.

• PEG 3350: Effective for many; onset 1–3 days; well tolerated in normal renal function.

• Magnesium salts: Fast and effective osmotic effect; risk of hypermagnesemia if renal function impaired.

• Stimulant laxatives (bisacodyl, senna): Rapid effect; best for short courses; chronic use may cause tolerance or cramping.

• Rectal agents: Quick local effect for distal stool; useful when oral therapy fails.

Biomarkers to evaluate when constipation is unexplained or persistent

Checking these labs helps identify contributing conditions and informs safe laxative choices:

• Serum magnesium: low magnesium can contribute to constipation; supplementation may relieve symptoms, but check before taking magnesium salts.

• TSH (thyroid stimulating hormone): hypothyroidism commonly slows gut transit and can present with constipation.

• Creatinine and eGFR: assess kidney function before using magnesium-containing osmotics because reduced clearance raises risk of hypermagnesemia.

Discuss abnormal results and appropriate therapy with your healthcare provider.

Dosing and usage considerations

• Always follow product labeling and your prescriber’s advice.

• Typical OTC examples (discuss with clinician):

  • Polyethylene glycol (PEG 3350): 17 g once daily mixed in water; adjust as needed.

  • Docusate sodium: commonly 100 mg 1–3 times daily.

  • Bisacodyl oral: commonly 5–15 mg once daily; rectal suppository: commonly 10 mg.

  • Magnesium products: dosing varies by formulation; use cautiously and only after lab review if kidney disease or other risks exist.

• Avoid combining multiple stimulant or osmotic agents without medical advice.

Safety notes and who should avoid specific therapies

• People with impaired kidney function (low eGFR) should avoid or use magnesium-containing laxatives only under medical supervision.

• Those with severe abdominal pain, persistent vomiting, fever, or signs of bowel obstruction should seek urgent care before using laxatives.

• Long-term daily stimulant laxative use is discouraged without clinician oversight.

• Pregnant or breastfeeding people should consult their clinician before starting laxatives or supplements.

Red flags — when to seek urgent care

Seek immediate medical attention if you experience:

• Severe abdominal pain or cramping.

• Persistent vomiting.

• No bowel movement with abdominal swelling or inability to pass gas.

• Fever or bloody stools.
  These signs may indicate bowel obstruction, impaction, or other urgent conditions.

Takeaways

• GLP‑1 therapies can contribute to constipation in some users; severity varies by person and dose.

• A stepwise plan starts with hydration, activity, and fiber, then moves to osmotic agents (PEG, magnesium where safe), stool softeners, and short-term stimulants if needed.

• Important biomarkers to check include magnesium, TSH, and creatinine/eGFR to guide therapy and safety.

• Avoid magnesium laxatives in significant renal impairment and seek urgent care for severe pain, vomiting, or no bowel movement with abdominal swelling.

• Work with your prescriber to consider dose adjustments or alternative GLP‑1 strategies if conservative measures fail.

Conclusion
Constipation related to GLP‑1 therapy such as Ozempic can often be managed with stepwise, evidence‑informed measures. Start with lifestyle and dietary tactics, progress to safe OTC options when required, monitor key biomarkers, and contact your healthcare team for persistent or severe symptoms. Personalized decisions about medication adjustments should always involve your clinician.

Join Mito to test 100+ biomarkers and get concierge-level guidance from your care team